<DOC>
	<DOC>NCT02979951</DOC>
	<brief_summary>The purpose of this European, multicentric, prospective, non-interventional study is to document and evaluate the efficacy and safety of the treatment of severely infected patients with intravenously administered fosfomycin, including patients with osteomyelitis, complicated urinary tract infection, nosocomial lower respiratory tract infection, bacterial meningitis/central nervous system infection, bacteraemia/sepsis, skin and soft tissue infection, endocarditis or other infections, each as far as covered by the respective nationally relevant SmPC.</brief_summary>
	<brief_title>Fosfomycin i.v. for Treatment of Severely Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Abscess</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Osteomyelitis</mesh_term>
	<mesh_term>Endocarditis</mesh_term>
	<mesh_term>Soft Tissue Infections</mesh_term>
	<mesh_term>Pneumonia, Bacterial</mesh_term>
	<mesh_term>Skin Diseases, Bacterial</mesh_term>
	<mesh_term>Intraabdominal Infections</mesh_term>
	<mesh_term>Bone Diseases, Infectious</mesh_term>
	<mesh_term>Meningitis, Bacterial</mesh_term>
	<mesh_term>Endocarditis, Bacterial</mesh_term>
	<mesh_term>Brain Abscess</mesh_term>
	<mesh_term>Central Nervous System Bacterial Infections</mesh_term>
	<mesh_term>Fosfomycin</mesh_term>
	<criteria>Male or female patients aged â‰¥ 18 years Treatment with fosfomycin according to the (national) Summary of Product Characteristics (SmPC) of fosfomycin i.v. Patients with osteomyelitis, complicated urinary tract infection, nosocomial lower respiratory tract infection, bacterial meningitis/central nervous system infection, bacteraemia/sepsis, skin and soft tissue infection, endocarditis or other infection, each as far as covered by the respective nationally relevant SmPC Written informed consent of the participant (or person in charge in case of patients incapable of giving consent) Previous documentation of the patient in the present study Patients participating in an interventional clinical trial Patients with known hypersensitivity to fosfomycin or any of the excipients Terminally ill patients Patients with "do not resuscitate order" Palliative treatment approach Failure of &gt; 3 of the following organ systems: respiratory system, nervous system, cardiovascular system, liver, coagulation, kidney Manifest Human Immunodeficiency Virus (HIV) disease (Acquired Immunodeficiency Syndrome, AIDS) Fosfomycin treatment as 4th line treatment or at later stage Patients with involvement of fungi or mycobacteria in the targeted infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Observational Study</keyword>
	<keyword>Non-Interventional Study</keyword>
	<keyword>Registries</keyword>
	<keyword>Prospective</keyword>
	<keyword>Monitored</keyword>
	<keyword>Multicentric</keyword>
	<keyword>International</keyword>
	<keyword>Fosfomycin</keyword>
	<keyword>Infectofos</keyword>
	<keyword>Fomicyt</keyword>
	<keyword>Bacterial Infections</keyword>
	<keyword>Gram-Negative Bacterial Infections</keyword>
	<keyword>Gram-Positive Bacterial Infections</keyword>
	<keyword>Bone Diseases, Infectious</keyword>
	<keyword>Osteomyelitis</keyword>
	<keyword>Central Nervous System Bacterial Infections</keyword>
	<keyword>Meningitis, Bacterial</keyword>
	<keyword>Encephalitis</keyword>
	<keyword>Brain Abscess</keyword>
	<keyword>Urinary Tract Infections</keyword>
	<keyword>Respiratory Tract Infections</keyword>
	<keyword>Pneumonia, Bacterial</keyword>
	<keyword>Skin Diseases, Bacterial</keyword>
	<keyword>Soft Tissue Infections</keyword>
	<keyword>Intraabdominal Infections</keyword>
	<keyword>Sepsis</keyword>
	<keyword>Bacteremia</keyword>
	<keyword>Endocarditis, Bacterial</keyword>
	<keyword>Treatment Outcome</keyword>
	<keyword>Clinical Efficacy</keyword>
	<keyword>Microbiological Efficacy</keyword>
	<keyword>Safety</keyword>
</DOC>